NA Selank Amidate Research: Terminus-Stabilised Anxiolytic Neuropeptide

NA Selank Amidate is the N-acetylated, C-amidated form of Selank, providing maximum exopeptidase resistance for the tuftsin-derived heptapeptide research tool. The two terminal modifications protect against aminopeptidase attack at the N-terminus and carboxypeptidase attack at the C-terminus, significantly extending the compound's stability in biological media compared to standard Selank.

Structural Design Rationale

The Selank sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro already has some intrinsic C-terminal stability from the terminal Pro residue (proline is a poor substrate for most carboxypeptidases due to its cyclic structure). NA Selank Amidate adds C-terminal amidation for comprehensive protection, while the N-terminal acetylation addresses the more vulnerable free amine at Thr1.

The central pharmacophore — Thr-Lys-Pro-Arg (the tuftsin-derived receptor-interacting core) — is completely preserved. Neither modification alters the mid-sequence that drives GABAergic, BDNF, and enkephalin-system interactions studied in Selank research.

Comparative Stability Research

The most direct research application of NA Selank Amidate is comparison with standard Selank under identical assay conditions. By running parallel experiments with:

• Standard Selank (both termini unprotected)
• Selank Amidate (C-terminus only protected)
• NA Selank Amidate (both termini protected)

Researchers can systematically characterise how metabolic stability affects apparent pharmacodynamic parameters. If NA Selank Amidate produces larger or more prolonged effects than standard Selank at the same nominal concentration, this indicates that degradation of the standard form was limiting its effective concentration in the assay — providing quantitative information about the contribution of enzymatic degradation to the observed pharmacology.

Research in GABAergic and Neuroprotective Models

NA Selank Amidate is used in the same research contexts as standard Selank — GABAergic signalling assays, BDNF expression studies, enkephalin degradation inhibition research, and immunomodulatory studies — but with extended stability enabling longer assay timepoints and more reliable dose-response characterisation.

Published Research References

Detailed Stability Mechanism

The two terminal modifications in NA Selank Amidate address distinct degradation pathways:

N-terminal acetylation. The alpha-amino group at Thr1 of standard Selank is susceptible to aminopeptidase attack — sequential cleavage of N-terminal amino acids one at a time. Acetylation of this amino group (CH3CO-NH-) neutralises its nucleophilicity and creates a steric and electronic barrier to aminopeptidase binding. N-acetyl peptides are not substrates for the vast majority of aminopeptidases, which require a free alpha-amino group for catalysis.

C-terminal amidation. The C-terminal carboxylic acid of Pro7 in standard Selank is susceptible to carboxypeptidase activity. The Pro residue itself provides some protection (carboxypeptidase A cannot cleave C-terminal proline due to steric constraints of the active site), but carboxypeptidase B-type enzymes can attack. Replacing -COOH with -CONH2 eliminates the carboxylate anion that coordinates to the carboxypeptidase active site zinc, making the amidated peptide resistant to carboxypeptidase attack.

Pharmacokinetic Research Applications

NA Selank Amidate's extended stability in biological media makes it the preferred form for studies where accurate pharmacokinetic characterisation is required:

Plasma stability assays. Incubating the peptide in plasma at 37°C over 0-240 minutes and measuring remaining intact peptide by LC-MS provides a direct stability comparison between standard Selank and NA Selank Amidate — a useful pre-experiment quality check for longer-duration studies.

Tissue distribution studies. For research examining whether Selank-derived compounds reach target tissues (brain, spinal cord, lymph nodes), NA Selank Amidate's extended half-life allows detection at tissue sampling timepoints that would show no intact standard Selank due to rapid degradation.

For laboratory and analytical research purposes only. Not for human or veterinary use.

Related: Standard Selank | Semax | Semax + Selank Blend
View NA Selank Amidate product and buy →

Selank Pharmacokinetics: Why Terminal Protection Matters

Standard Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) already has some terminal protection advantages over simpler peptides. The C-terminal proline is a poor carboxypeptidase A substrate (the active site cannot accommodate proline's cyclic side chain in the carboxypeptidase cleavage geometry). However, carboxypeptidase B-type enzymes that cleave C-terminal basic residues (Arg, Lys) are not blocked by C-terminal Pro — they would need to sequentially remove the Pro first through some minor carboxypeptidase A activity before reaching the Arg at position 4.

The N-terminal Thr1 in standard Selank is the more vulnerable terminus. Aminopeptidases that cleave N-terminal amino acids (particularly dipeptidyl aminopeptidases like DPP-IV and DPP-8/9) can act at Thr1-Lys2 bonds. DPP-IV specifically requires X-Pro or X-Ala at positions 1-2 for optimal cleavage, and Thr-Lys is not an ideal DPP-IV substrate — but other aminopeptidases (CD26-independent) can still act at the free N-terminal Thr.

N-acetylation in NA Selank Amidate eliminates the free alpha-amine that all aminopeptidases require for N-terminal substrate recognition. The acetyl group neutralises the positive charge and adds steric bulk, creating a comprehensive aminopeptidase block that the natural Pro-Gly-Pro C-terminal extension does not provide for the N-terminus.

Research Comparison Designs: Three-Member Selank Series

The most informative Selank research design uses three parallel treatment groups: (1) Standard Selank (free N-terminal, free C-carboxyl), (2) Selank Amidate (free N-terminal, C-amide), and (3) NA Selank Amidate (N-acetyl, C-amide). This three-member series allows:

Attributing effects to specific terminus: Any difference between Standard Selank and Selank Amidate is attributable to C-terminal amidation; any difference between Selank Amidate and NA Selank Amidate is attributable to N-terminal acetylation; any difference between Standard Selank and NA Selank Amidate represents the combined effect of both modifications.

Stability correction: At any given timepoint in a long-duration experiment, the NA Selank Amidate concentration remains closer to the nominal added concentration than Standard Selank. Measuring effective concentrations by LC-MS at experimental endpoints allows quantitative correction for stability differences.

Dose-response shift: If NA Selank Amidate produces a left-shifted dose-response curve (lower EC50) compared to Standard Selank in a 24-hour incubation assay, this directly quantifies the pharmacokinetic improvement from terminal modification.

Frequently Asked Questions

Does N-acetylation affect the receptor-binding pharmacophore of Selank?
The receptor-interacting region of Selank is the central Lys-Pro-Arg-Pro segment (positions 2-5 of the standard sequence), which corresponds to the tuftsin receptor-binding pharmacophore. N-acetylation at Thr1 modifies the extreme N-terminal residue that is not part of the central pharmacophore. The additional methyl group and carbonyl from acetylation create a compact N-terminal cap that does not extend into the receptor-binding region. Published SAR research on tuftsin analogues supports that N-terminal modifications outside the Lys-Pro-Arg core are tolerated without significant affinity loss — analogous to how many neuropeptides retain activity when N-acetylated.

Is NA Selank Amidate pharmacologically equivalent to standard Selank in short-duration assays?
For assays lasting 1-4 hours (typical for calcium signalling, cAMP measurement, or acute receptor binding), the stability advantage of NA Selank Amidate is minimal — standard Selank degrades little in this timeframe and both compounds behave essentially equivalently. The modification advantage becomes significant in assays lasting 12-72 hours (gene expression changes, cell proliferation, chronic signalling studies) where cumulative degradation of Standard Selank reduces effective concentration substantially.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide

Research Tool Selection: NA Selank Amidate vs Standard Selank Summary

For researchers deciding between Standard Selank and NA Selank Amidate for their specific application, the following decision framework summarises the key considerations:

Use Standard Selank when: (1) Reproducing published Russian research that used standard Selank formulation; (2) Assay duration is less than 4 hours (minimal stability difference); (3) Mechanistic research specifically examining Pro-Gly-Pro C-terminal peptide biology alongside the tuftsin pharmacophore; (4) Budget considerations favour the unmodified form for preliminary dose-finding experiments.

Use NA Selank Amidate when: (1) Assay duration exceeds 6 hours (gene expression, cell proliferation, chronic signalling studies); (2) In vivo pharmacokinetic research requiring extended plasma half-life; (3) Quantitative dose-response work requiring stable effective concentrations throughout the experiment; (4) Stability-activity relationship research comparing the three-member Selank series (Standard, Amidate, NA Amidate).

Both forms share: Identical central tuftsin-derived pharmacophore (Lys-Pro-Arg-Pro core), identical Pro-Gly-Pro C-terminal stability extension, greater than or equal to 98% HPLC purity verification, and research-use classification. Neither form is approved for human use. Both are supplied as lyophilised powder for reconstitution.